<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335628">
  <stage>Registered</stage>
  <submitdate>25/06/2010</submitdate>
  <approvaldate>8/07/2010</approvaldate>
  <actrnumber>ACTRN12610000550000</actrnumber>
  <trial_identification>
    <studytitle>Efficiency of carbetocin in the prevention of the postpartum  haemorrhage :a clinical double-blinded randomized study .</studytitle>
    <scientifictitle>Comparison of the effectiveness of carbetocin vs oxytocin in managing the third stage of labor in a group of women with risk factors for postpartum hemorrhage.</scientifictitle>
    <utrn>U1111-1115-5309</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>postpartum haemorrhage</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>carbetocin ampule x 100 mcg diluted in 10 cc of saline administered as a single intravenous bolus dose in the management of the third phase  of labor.</interventions>
    <comparator>oxytocin  ampule x 10 units diluted in 10 cc of saline administered as a single intravenous bolus in the  managing of the third period of the labor followed by an intravenous administration of 60 units of oxytocin diluted in 1000 cc of saline (saline solution 0.9%) at a rate de 80 mL/h over 12 hours starting immediately after delivery of the infant.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is average postpartum bleeding within 24 hours of delivery in each of the groups. the volume of blood will be collected from diapers every 6 hours for 24 hours. Previously, design a linear regression which shows the volume of bleeding according to the weight of each diaper.

each of the diapers collected is weighed and get the respective volume derived from the linear regression. The sum of the four diapers provides postpartum bleeding within 24 hours.</outcome>
      <timepoint>first 24 hours after birth</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>percentage of adverse drug effects. Headache, nauseas, difficulty to breathe, abdominal pain , syncope, dizziness, changes in the arterial pressure, metallic flavor.These adverse effects are gathered across surveys realized at 12 and 24 hours after applied the intervention on the management of the third phase of labor in each group .</outcome>
      <timepoint>at 12 and 24 hours after administration of the intervention on the management of the third phase of labor in each group .</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>percentage of additional interventions to control postpartum bleeding. Use of additional doses of oxytocin, misoprotol, derived from the ergot, uterine massage, blood products, surgical intervention in order to stop bled. These interventions  are gathered across surveys realized at  24 hours after applied applied the intervention on the management of the third phase of labor in each group .</outcome>
      <timepoint>first 24 hours after birth</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.  Pregnancy over 34 weeks.
2. Hold at history a risk factor for postpartum haemorrhague as nulliparous, multiple pregnancy, hypertensive disease, induction of labor, fetal macrosomia fetus, more than 35 years, obesity, second period of prolonged labor, precipitate labor, chorioamnionitis and  prolonged third period of labor.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Mental retardation.
2. Coagulation disorder.
3. Renal failure.
4. Liver failure.
5. Heart failure.
6. Heart rhythm disorders.
7. Central placenta previa total.
8. Indication of caesarean.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Enrolling: Once the patient enters to room of childbirths and fulfills the criteria of incorporation and exclusion one invites to take part and to signing the informed consent to be included in the study.
The assignment of the treatment is carried out to the beginning of the second phase of the labor. The doctor in charge of the room of childbirths, across telephonic line, requests a code of assignment. The treatment is in sealed opaque envelopes with the respective code and his content does not allow to know which treatment is applied</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/07/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>milton gomez</primarysponsorname>
    <primarysponsoraddress>avenue 64A #13a 74  apartment 303F
Santiago de Cali
Valle del cauca.
postal code of the city of Cali: 76001000</primarysponsoraddress>
    <primarysponsorcountry>Colombia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>clinica versalles</fundingname>
      <fundingaddress>Avenue 5 AN #23-45
Santiago de Cali.
Valle del cauca.
postal code of the city of Cali: 76001000</fundingaddress>
      <fundingcountry>Colombia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>BIOTEFAR laboratory</sponsorname>
      <sponsoraddress>street 24 north #8 North -50 second floor 
Santiago de Cali
Valle del cauca.
postal code of the city of Cali: 76001000</sponsoraddress>
      <sponsorcountry>Colombia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Pontificia Universidad Javeriana</othercollaboratorname>
      <othercollaboratoraddress>street 18 # 118-250 Santiago de Cali
Valle del Cauca.
postal code of the city of Cali: 76001000</othercollaboratoraddress>
      <othercollaboratorcountry>Colombia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Postpartum haemorrhage (PPH) is a major cause of morbidity and mortality in the world.  The present study aims to compare the effectiveness of carbetocin and oxytocin in the prevention of bleeding that occurs within 24 hours after delivery, in a group of pregnant women with risk factors for PPH.</summary>
    <trialwebsite>nothing</trialwebsite>
    <publication>nothing</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>comite de etica Clinica versalles</ethicname>
      <ethicaddress>Avenue 5 north # 23-42
Santiago de Cali.
Valle del cauca.
postal code of the city of Cali: 76001000</ethicaddress>
      <ethicapprovaldate>17/05/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>3/05/2010</ethicsubmitdate>
      <ethiccountry>Colombia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Milton cesar Gomez gomez</name>
      <address>avenue 64A #13A -74 apto 303F
Santiago de Cali. 
Valle del Cauca.
postal code of the city of Cali: 76001000</address>
      <phone>+57 315 5485450 cell phone</phone>
      <fax>+57 2 3395019 telephone</fax>
      <email>micegogo@hotmail.com</email>
      <country>Colombia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Milton cesar Gomez gomez</name>
      <address>avenue 64A #13A -74 apto 303F
Santiago de Cali. 
Valle del Cauca.
postal code of the city of Cali: 76001000</address>
      <phone>+57 315 5485450 cell phone</phone>
      <fax>+57 2 3395019  telephone</fax>
      <email>micegogo@hotmail.com</email>
      <country>Colombia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Milton cesar Gomez gomez</name>
      <address>avenue 64A #13A -74 apto 303F
Santiago de Cali. 
Valle del Cauca.
postal code of the city of Cali: 76001000</address>
      <phone>+57 315 5485450 cell phone</phone>
      <fax>+ 57 2 3395019 telephone and fax</fax>
      <email>micegogo@hotmail.com</email>
      <country>Colombia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>